Mary Adams

TL;DR: It is suggested that lenalidomide has the potential to enhance the rituximab-induced killing of NHL cell lines and primary B-cell chronic lymphocytic leukemia cells via a NK cell-mediated and monocyte-mediated ADCC mechanism in vitro, providing a strong rationale for the combination of lenalidumide with IgG1 antibodies to target tumor-specific antigens in patients with cancer.

TL;DR: The inhibitory effects of apremilast on pro‐inflammatory responses of human primary peripheral blood mononuclear cells, polymorphonuclear Cells, natural killer cells and epidermal keratinocytes were explored in vitro, and in a preclinical model of psoriasis.

TL;DR: The work experiences of staff in a MfOP service impacted directly on patient care experience, leading staff to seek job satisfaction through caring for 'poppets', leaving less favoured patients to receive less personalised care.

TL;DR: Current systematic challenges to patient recruitment and retention in clinical studies more generally as seen from the perspective of staff at the 'sharp end’ of recruiting are highlighted.

TL;DR: Lenalidomide enhances the ability of IgG1-isotype antibodies to mediate ADCC of solid tumor cells, the extent of which is largely dependent on NKG2D–NKG2d ligand interactions, but appears to be independent of MIC-A/B.